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Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue
factor and arterial thrombosis
Abstract
BACKGROUND: The phytosterol guggulsterone is a potent anti-inflammatory mediator with less side
effects than classic steroids. This study assesses the impact of guggulsterone on tissue factor (TF)
expression and thrombus formation. METHODS AND RESULTS: Guggulsterone inhibited
TNF-alpha-induced endothelial TF protein expression and surface activity in a concentration-dependent
manner; in contrast, dexamethasone did not affect TNF-alpha-induced TF expression. Guggulsterone
enhanced endothelial tissue factor pathway inhibitor and impaired plasminogen activator inhibitor-1 as
well as vascular cell adhesion molecule-1 protein. Real-time polymerase chain reaction revealed that
guggulsterone inhibited TNF-alpha-induced TF mRNA expression; moreover, it impaired activation of
the MAP kinases JNK and p38, while that of ERK remained unaffected. In vivo, guggulsterone inhibited
TF activity and photochemical injury induced thrombotic occlusion of mouse carotid artery.
Guggulsterone also inhibited TF expression, proliferation, and migration of vascular smooth muscle
cells in a concentration-dependent manner. CONCLUSIONS: Guggulsterone inhibits TF expression in
vascular cells as well as thrombus formation in vivo; moreover, it impairs vascular smooth muscle cell
activation. Hence, this phytosterol offers novel therapeutic options, in particular in inflammatory
diseases associated with an increased risk of thrombosis.
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Abstract 
 
Background: The phytosterol guggulsterone is a potent anti-inflammatory mediator 
with less side effects than classic steroids. This study assesses the impact of 
guggulsterone on tissue factor (TF) expression and thrombus formation. 
Methods and Results: Guggulsterone inhibited TNF-α induced endothelial TF 
protein expression and surface activity in a concentration-dependent manner; in 
contrast, dexamethasone did not affect TNF-α induced TF expression. 
Guggulsterone enhanced endothelial tissue factor pathway inhibitor and impaired 
plasminogen activator inhibitor-1 as well as vascular cell adhesion molecule-1 
protein. Real-time polymerase chain reaction revealed that guggulsterone inhibited 
TNF-α induced TF mRNA expression; moreover, it impaired activation of the MAP 
kinases JNK and p38, while that of ERK remained unaffected. In vivo, guggulsterone 
inhibited TF activity and photochemical injury induced thrombotic occlusion of mouse 
carotid artery. Guggulsterone also inhibited TF expression, proliferation, and 
migration of vascular smooth muscle cells in a concentration-dependent manner. 
Conclusions: Guggulsterone inhibits TF expression in vascular cells as well as 
thrombus formation in vivo; moreover, it impairs vascular smooth muscle cell 
activation. Hence, this phytosterol offers novel therapeutic options, in particular in 
inflammatory diseases associated with an increased risk of thrombosis. 
 
 
Keywords 
arterial thrombosis - photochemical injury - phytosterol - tissue factor 
 3 
Introduction 
 
Vascular inflammation promotes the progression of coronary artery disease; 
moreover, it triggers acute coronary syndromes [13, 15]. Tissue factor (TF) is 
regulated by a variety of inflammatory mediators and initiates activation of 
coagulation. Consistent with this observation, experimental evidence has revealed an 
important contribution of TF to arterial thrombosis, the key event in acute coronary 
syndromes [28, 30, 31]. Clinical observations have indeed confirmed that cytokine 
concentrations high enough to induce endothelial expression of TF are reached at 
the culprit lesion of patients with acute coronary syndrome [19].  
Guggulsterone [4,17(20)-pregnadiene-3,16-dione] is a plant derived steroid 
isolated from the gum resin of the tree commiphora mukul, which has been 
extensively used in Ayurvedic medicine to treat several conditions associated with 
inflammation such as hyperlipidemia, obesity, and arthritis [1, 14, 23, 34]. 
Guggulsterone indeed exerts strong anti-inflammatory effects by suppressing the 
activation of the transcription factor NF-kappa B in response to different agonists 
including tumor necrosis factor α (TNF-α) [22]. In line with its anti-inflammatory 
properties, previous studies revealed that guggulsterone is able to impair LDL 
oxidation, thereby delaying the progression of atherosclerosis [3, 37]. 
Since guggulsterone is an anti-inflammatory, well-tolerated, natural drug, this 
study was designed to investigate its impact on cytokine induced TF expression as 
well as arterial thrombus formation in vivo. 
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Materials and Methods 
 
Cell culture 
Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland) and 
human aortic vascular smooth muscle cells (VSMCs) were cultured as described 
[24]. THP-1 cells (LGC Promochem, Molsheim, France) were kept in RPMI 
containing 10% fetal calf serum (FCS). Adhering cells were grown to confluence and 
rendered quiescent for 24 hours before stimulation with 5 ng/mL TNF-α (R&D, 
Minneapolis, MN). Cells were pretreated with guggulsterone, dexamethasone (all 
from Sigma, Buchs, Switzerland), or GW-4064  (Tocris Bioscience, Ellisville, MI) for 
60 min before stimulation. Cytotoxicity was assessed by a colorimetric assay to 
detect lactate dehydrogenase release (Roche, Basel, Switzerland) [25]. 
For proliferation, VSMCs were cultured for 24 hours in Dulbecco’s modified 
Eagle medium (DMEM) with 10% FCS. Cells were then serum withdrawn for 48 
hours before stimulation with 10% FCS in the presence of different guggulsterone 
concentrations. Media were replaced daily, and cell number was determined after 3 
days with a hemocytometer (Assisten, Sondheim, Germany) [5]. For migration, 
VSMCs were cultured for 24 hours in DMEM with 10% FCS and then harvested and 
resuspended (500’000 cells/mL) for analysis of migration in response to platelet-
derived growth factor BB (10 ng/mL) in a modified Boyden chamber system 
(NeuroProbe Inc, Gaithersburg, MD) [5].  
 
Western blot  
Protein expression was determined by Western blot analysis as described 
[26]. Antibodies against human TF and tissue factor pathway inhibitor (TFPI; both 
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from American Diagnostica, Stamford, CT) were used at 1:2000 dilution. Antibodies 
against phosphorylated p38 MAP kinase (p38), p44/42 MAP kinase (extracellular 
signal–regulated kinase [ERK]), and c-Jun NH2-terminal kinase (JNK; all from Cell 
Signaling, Danvers, MA) were used at 1:1000, 1:5000, and 1:1000 dilution, 
respectively. Antibodies against total p38, ERK, and JNK (all from Cell Signaling) 
were used at 1:3000, 1:2000, and 1:1000 dilution, respectively. Antibodies against 
vascular cell adhesion molecule-1 (VCAM-1; R&D) and plasminogen activator 
inhibitor-1 (PAI-1; Santa Cruz) were applied at 1:2000 and 1:4000 dilution, 
respectively. Anti-goat glyceraldehyde-3-phosphate dehydrogenase antibody 
(GAPDH; Chemicon, Temecula, CA) was applied to ensure equal protein loading 
(1:20000 dilution). Proteins were detected with a horseradish peroxidase–linked 
secondary antibody (Amersham). 
 
Real-time PCR 
All real-time PCR experiments were performed in triplicate using the SYBR 
Green JumpStart kit (Sigma) in an MX3000P PCR cycler (Stratagene, Amsterdam, 
The Netherlands). Each reaction (25 μl) contained 2 μl cDNA, 1 pmol of each primer, 
0.25 μl of internal reference dye, and 12.5 μl of JumpStart Taq ReadyMix (containing 
buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase, and JumpStart Taq 
antibody). The following primers were used: human tissue factor (F3): sense primer: 
5’-TCCCCAGAGTTCACACCTTACC–3’ (bases 508-529 of F3 cDNA; NCBI no. NM 
001993), antisense primer: 5’–TGACCACAAATACCACAGCTCC–3’ (bases 892-913 
of F3 cDNA; NCBI no. NM 001993); human L28: sense primer: 5’–
GCATCTGCAATGGATGGT-3’, antisense primer: 5’–TGTTCTTGCGGATCATGTGT-
3’. The amplification program consisted of 1 cycle at 95˚C for 10 min followed by 40 
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cycles with a denaturing phase at 95˚C for 30 s, an annealing phase at 60˚C for 1 
min, and an elongation phase at 72˚C for 1 min. PCR products were analyzed on an 
ethidium bromide stained 1% agarose gel, and a melting curve analysis was 
performed after amplification to verify the accuracy of the amplicon. In each real-time 
PCR run for F3 and L28, a calibration curve was included that was generated from 
serial dilutions of the respective purified amplicon [24, 27].  
 
TF activity 
TF activity was analyzed at the surface of HAEC and in mouse carotid artery 
tissue homogenates, respectively, using a colorimetric assay (American Diagnostica) 
according to the manufacturer’s recommendations with some modifications as 
described [5]. Right carotid arteries were homogenized in 50 μl of lysis buffer (50 
mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100 pH 7.4) 5 hrs after oral gavage of 
guggulsterone (100 mg/kg) or vehicle (0.5% methyl cellulose, 10 ml/kg) and left to 
stand on ice for 30 minutes. TF/FVIIa converted factor X to factor Xa, which was 
measured by its ability to metabolize a chromogenic substrate. A standard curve with 
lipidated human TF was performed to assure that measurements were taken in the 
linear range of detection. 
 
 
Carotid artery thrombosis model 
16 week old C57BL/6 mice weighing on average 28±1 g were anesthetized by 
intraperitoneal injection of 2.4 mg sodium pentobarbital (Butler, Columbus, OH) as 
described [5]. Rose bengal (Fisher Scientific, Fair Lawn, NJ) was diluted to 12 mg/mL 
in phosphate-buffered saline and then injected into the tail vein at a dose of 50 mg/kg. 
Mice were secured in a supine position, placed under a dissecting microscope 
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(Olympus C-4040 Zoom), and the right common carotid artery was exposed following 
a midline cervical incision. A Doppler flow probe (Model 0.5 VB, Transonic Systems, 
Ithaca, NY) was applied and connected to a flowmeter (Transonic, Model T106). 6 
minutes after rose bengal injection, a 1.5-mW green light laser (540 nm; Melles Griot, 
Carlsbad, CA) was applied to the site of injury at a distance of 6 cm for 60 minutes or 
until thrombosis occurred. From the onset of injury, blood flow was monitored for 
120 minutes, at which time the experiment was terminated. Occlusion was defined as 
flow ≤0.1 ml/min for at least 1 minute [8]. Mice were divided into 2 groups: 
guggulsterone (oral gavage, 5 hours before surgery; 100 mg/kg guggulsterone 
diluted in 0.5% methyl cellulose in an injection volume of 10 ml/kg), or vehicle control 
(0.5 % methyl cellulose).  
 
Statistics 
Data are presented as mean±SEM. Statistical analysis was performed by 2-
tailed unpaired Student’s t test or ANOVA as appropriate. A probability value of <0.05 
was considered significant. 
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Results 
 
Guggulsterone inhibits TNF-α induced TF protein expression and activity in 
vascular cells 
HAECs were stimulated with TNF-α (5 ng/ml) for 5 hours in the presence or 
absence of guggulsterone. Guggulsterone inhibited TNF-α induced TF expression in 
a concentration-dependent manner with a maximal effect occurring at 10-4 mol/L 
(n=7; P<0.05; Fig. 1A); similarly, it impaired TNF-α induced TF surface activity (n=4; 
P<0.05; Fig. 1B). Guggulsterone also inhibited TF expression in VSMCs (n=4; 
P<0.05; Fig. 1C), but not in THP-1 cells (n=5; P=N.S.; Figure 1D). In contrast to 
guggulsterone, dexamethasone did not affect TNF-α induced TF expression (n=6; 
P=NS; data not shown).  
 
Guggulsterone enhances endothelial TFPI and inhibits PAI-1 as well as VCAM-1 
expression 
Guggulsterone enhanced basal expression of TFPI in a concentration-
dependent manner (n=3; P<0.05; Fig. 2A), but did not affect TNF-α induced TFPI 
expression (n=3; P=N.S.; Fig. 2A). Guggulsterone inhibited basal expression of PAI-1 
in a concentration-dependent manner (n=7; P<0.05; Fig. 2B), and a similar effect was 
observed after TNF-α stimulation (n=7; P<0.05; Fig. 2B). Moreover, guggulsterone 
inhibited TNF-α induced VCAM-1 expression in a concentration-dependent and 
potent manner (n=7; P<0.05; Fig. 2C). In contrast to guggulsterone, dexamethasone 
only weakly impaired TNF-α induced VCAM-1 expression (15% inhibition; n=3; 
P<0.05; data not shown). 
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Guggulsterone is not toxic for vascular cells 
HAECs and VSMCs were treated with increasing concentrations of 
guggulsterone or dexamethasone for 6 hours. Morphological examination of the cells 
did not reveal any changes (n=4-14; data not shown). Moreover, no signs of toxicity 
were detected by LDH release (n=4-14; P=N.S.; data not shown). 
 
 
Guggulsterone inhibits endothelial TF mRNA expression 
Real-time PCR revealed that TF mRNA expression was induced after 2 hours 
of TNF-α stimulation (n=4; P<0.05; Fig. 3). Guggulsterone inhibited TNF-α induced 
TF mRNA expression in a concentration-dependent manner (n=4; P<0.05; Fig. 3).  
 
Guggulsterone impairs endothelial TF expression via MAP kinase inhibition 
 
The MAP kinases JNK, p38 and ERK were transiently activated by TNF-α 
(n=5; Fig. 4A). Guggulsterone inhibited phosphorylation of JNK and p38, while that of 
ERK remained unaffected (n=5; Fig. 4 A and B). No significant change in total 
expression of MAP kinases was observed at any time point with or without 
guggulsterone. To verify the involvement of MAP kinases in TNF-α induced TF 
expression, the action of MAP kinase inhibitors was examined. PD98059, SP600125, 
and SB203580, which specifically inhibit ERK, JNK, and p38, respectively, 
significantly impaired TF expression after TNF-α stimulation (n=6; P<0.05 for TNF-α 
alone versus each inhibitor; Fig. 4C). 
 
Farnesoid X receptor (FXR) does not mediate the effect of guggulsterone 
 HAECs were stimulated with TNF-α (5 ng/ml) for 5 hours after a 1 hour 
treatment with guggulsterone (10-4M) or GW-4064 (10-5M), a selective and potent 
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FXR agonist. Guggulsterone and GW-4064 both decreased TNF-alpha induced 
endothelial TF protein expression with similar potency (n=4; *P<0.05). The effect of 
guggulsterone remained unaltered following treatment with the FXR agonist GW-
4064 (n=4; P=N.S.). No cytotoxic effect of either substance was observed as 
measured by LDH release (data not shown).  
 
Guggulsterone inhibits TF activity and arterial thrombosis in vivo 
Treatment with guggulsterone (100 mg/kg) impaired TF activity in mouse 
carotid artery in vivo (n≥4; P<0.05 for guggulsterone vs. vehicle; Fig. 5A). 
Photochemical injury is an established model of TF depending arterial thrombosis [4]. 
Initial blood flow in carotid artery of vehicle-treated mice equalled 0.58±0.03 ml/min 
(n=4); these mice developed thrombotic occlusion within a mean occlusion time of 
36.06±2.12 minutes (n=4; Fig. 5B). Guggulsterone treated mice exhibited similar 
initial blood flow (0.67±0.09 ml/min; n=7; P=N.S. for guggulsterone vs. vehicle), but 
developed thrombosis within a mean occlusion time of 55.51±4.83 minutes (n=7; 
P<0.05 for guggulsterone vs. vehicle; Fig. 5B).   
 
Guggulsterone inhibits proliferation and migration of human VSMCs 
Guggulsterone inhibited VSMC proliferation in response to 10% FCS in a 
concentration-dependent manner by 82% at the maximal concentration (n=11; 
P<0.05; Fig. 6A). Likewise, guggulsterone inhibited VSMC migration in response to 
10 ng/mL platelet-derived growth factor-BB in a concentration-dependent manner by 
99% at the maximal concentration (n=5; P<0.05; Fig. 6A). 
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Discussion 
 
This study demonstrates that the anti-inflammatory phytosterol guggulsterone 
inhibits TF in HAECs and VSMCs; this effect is related to impaired activation of the 
MAP kinases JNK and p38 in endothelial cells, resulting in a diminished level of TF 
mRNA, protein, and activity. Consistent with these observations, guggulsterone 
inhibits TF activity as well as thrombotic occlusion of mouse carotid artery in vivo. 
Moreover, guggulsterone impairs proliferation and migration of vascular smooth 
muscle cells. Hence, guggulsterone may be considered as a novel anti-thrombotic 
agent for treating inflammatory vascular disorders. 
Chronic systemic inflammation, as encountered in rheumatoid arthritis or 
systemic lupus erythematodes, is associated with a considerably increased risk of 
cardiovascular disease [13, 35]. TF plays a crucial role in inflammation-induced 
coagulation as it is upregulated in vascular cells and in vivo by several inflammatory 
mediators [16, 28, 32]. As a consequence, recent efforts have focused on novel 
strategies for targeting TF. The phytosterol guggulsterone seems to be a suitable 
candidate, as it exhibits potent anti-inflammatory and anti-thrombotic properties.  
Significant impairment of TF expression in vitro occurred at concentrations as 
low as 10 µM. Up to now, the pharmacokinetics of guggulsterone in humans remain 
unknown; however, clinical trials performed in humans indicate that doses up to 6 g 
per day are safe and well tolerated [29]. This dose correlates well to that applied in 
our mouse experiments (100 mg/kg bodyweight). A study performed in rats revealed 
that 50 mg/kg bodyweight oral application of guggulsterone resulted in peak plasma 
concentrations of 3.2 µM [36]. In view of the above, the guggulsterone concentrations 
applied in vitro may reasonably well match the plasma concentrations reached in our 
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in vivo experiments. 
 Activation of MAP kinases mediates TF expression in response to many 
stimuli [18, 25, 28, 30]. Guggulsterone impaired endothelial TF expression by 
specifically decreasing phosphorylation of JNK and p38, but not ERK, and consistent 
with MAP kinase inhibition, guggulsterone promoted a strong reduction in TNF-α 
induced TF mRNA. Hence, in endothelial cells, the inhibitory effect of guggulsterone 
is related to MAP kinase inhibition and occurs at the transcriptional level. Since TNF-
α regulates TF expression in vascular smooth muscle cells via activation of MAP 
kinases as well, its inhibitory effect in this cell type may be similar to that in 
endothelial cells. This profile of action is remarkably similar to that of 
dimethylsulfoxide, another inhibitor of TF expression proposed for application on 
drug-eluting stents [5]. 
Guggulsterone is an antagonist of the farnesoid x receptor (FXR), a key 
regulator of cholesterol homeostasis[33]. Recent studies demonstrate that FXR is 
expressed and functional in vascular endothelial cells indicating that FXR may play a 
role in endothelial homeostasis and serve as a novel molecular target for 
manipulating vascular inflammation [4, 11, 17]. FXR is activated by bile acids such as 
chenodeoxycholic acid (CDCA); in addition, synthetic FXR agonists such as GW4064 
have been developed. Both guggulsterone and GW-4064 decreased TNF-alpha 
induced endothelial TF expression with similar potency; moreover, the effect of 
guggulsterone on endothelial TF expression remained unaltered in the presence of 
GW-4064. These observations suggest that the antithrombotic effects of 
guggulsterone occur independent of FXR inhibition.  
 TF activity is counterbalanced by its endogenous inhibitor TFPI, which is 
mainly produced by endothelial cells; the balance of these two factors is indeed 
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essential in determining thrombus formation [6]. Guggulsterone enhanced basal TFPI 
expression, which underlines the anti-thrombotic properties of this drug. However, 
TFPI release remained unaltered in TNF-α stimulated cells, indicating that the effect 
of guggulsterone on TFPI expression depends on the activation status of the cells. 
Hence, in an inflammatory environment, the effect of guggulsterone on TFPI 
expression appears to be overcome by the prothrombotic action of inflammatory 
mediators. However, under these circumstances, guggulsterone inhibited TF 
expression, and the lower TF expression in cytokine stimulated cells was not 
counteracted by a parallel decrease in TFPI; therefore, guggulsterone would be 
expected to exert potent antithrombotic actions even in an inflammatory environment 
by reducing TF instead of enhancing TFPI expression. PAI-1 is a serpin suppressing 
fibrinolysis by inhibiting the activity of tissue plasminogen activator (tPA). PAI-1 levels 
are elevated in patients with diabetes mellitus and coronary artery disease [2, 21] 
and are associated with an enhanced risk of coronary events [10, 12]. Besides its 
effects on TF and TFPI, guggulsterone downregulated PAI-1 expression both in 
quiescent and TNF-α stimulated cells; hence, guggulsterone may be particularly 
beneficial in patients with diabetes mellitus. 
Photochemical injury was selected for examining thrombus formation because 
it is an established protocol for TF-dependent arterial thrombosis in vivo [5, 7, 8]. 
Guggulsterone inhibited thrombotic occlusion, indicating that it may protect from 
thrombus formation. Indeed, inhibition of TF activity in the mouse carotid artery within 
5 hours of guggulsterone administration was confirmed and is the most likely 
explanation for the effect of guggulsterone on thrombus formation.  
Migration and proliferation of VSMCs are crucial events involved in neointima 
formation and restenosis after percutaneous revascularisation. Hence, substances 
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are applied on drug-eluting stents to reduce restenosis through inhibition of VSMC 
activation. This study demonstrates that guggulsterone effectively inhibits VSMC 
proliferation and migration. In addition to VSMC, TF has been implicated in the 
pathogenesis of neointima formation and stent thrombosis [20, 24, 27]. The 
pronounced inhibition of both VSMC activation and TF expression renders 
guggulsterone an attractive candidate for application on drug-eluting stents. 
 In summary, this study demonstrates that guggulsterone impairs TF in 
vascular cells and prevents thrombotic occlusion in vivo; further, guggulsterone 
inhibits VSMC proliferation and migration. These findings may offer new therapeutic 
approaches to prevent thrombosis in chronic inflammatory disorders or in the context 
of drug-eluting stents. The known ability of guggulsterone to inhibit platelet 
aggregation may indeed be very important in this regard [9]. However, further in vivo 
studies are needed to assess potential therapeutic effects of guggulsterone on 
neointima formation. Moreover, additional studies need to clarify whether 
guggulsterone’s effects are modulated by differences in genetic background, lifestyle 
or diet [29]. Only then can specific applications of guggulsterone for the treatment of 
vascular disease be developed and tested in humans. 
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Figure legends 
 
Figure 1: Guggulsterone inhibits TF protein expression and activity 
A. Guggulsterone inhibits TNF-α induced TF protein expression of human aortic 
endothelial cells (HAECs) (P<0.05 vs TNF-α alone). B. Guggulsterone inhibits TNF-α 
induced TF surface activity of HAECs (P<0.05 vs TNF-α alone). C. Guggulsterone 
inhibits TNF-α induced TF protein expression of human aortic vascular smooth 
muscle cells (P<0.05 vs TNF-α alone). D. Guggulsterone does not affect TNF-α 
induced TF protein expression of THP-I cells (P=N.S. vs TNF-α alone). Values are 
indicated as percent of TNF-α alone; all blots are normalized to GAPDH expression. 
 
Figure 2: Guggulsterone enhances endothelial TFPI and impairs PAI-1 as well 
as VCAM-1 expression 
A. Guggulsterone enhances basal TFPI expression (P<0.05 vs control), but does not 
affect TNF-α induced TFPI expression (P=N.S. vs TNF-α alone). B. Guggulsterone 
inhibits basal PAI-1 expression (P<0.05 vs control), and a similar effect is observed 
after TNF-α stimulation (P<0.05 vs TNF-α alone). C. Guggulsterone inhibits TNF-α 
induced VCAM-1 expression (P<0.05 vs control). Values are indicated as percent of 
control or TNF-α alone; all blots are normalized to GAPDH expression. 
 
Figure 3: Guggulsterone inhibits endothelial TF mRNA expression 
Real-time PCR reveals that guggulsterone inhibits TNF-α induced TF mRNA 
expression (P<0.05 vs TNF-α alone). Values are indicated as percent of TNF-α alone 
and normalized to L28 expression. 
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Figure 4: Guggulsterone impairs endothelial TF expression via MAP kinase 
inhibition 
A. The MAP kinases JNK, p38, and ERK are transiently activated by TNF-α (5 
ng/ml). Guggulsterone inhibits phosphorylation of JNK and p38, but not ERK. No 
significant change in total expression of MAP kinases is observed. B. Inhibition of 
MAP kinase activation by guggulsterone (P<0.05 vs TNF-α alone). C. PD98059, 
SB203580, and SP600125, specifically inhibiting ERK, p38, and JNK, respectively, 
impair TF expression after TNF-α stimulation  (P<0.05 for TNF-α alone vs each 
inhibitor). 
 
Figure 5: Guggulsterone inhibits TF activity and thrombotic occlusion in vivo 
A. Guggulsterone inhibits TF activity in mouse carotid artery (n=4-7; P<0.03). B. 
Time to thrombotic occlusion after mouse carotid artery photochemical injury in vivo. 
Treatment is performed with guggulsterone (100 mg/kg) or vehicle (methyl cellulose), 
and laser injury is initiated at time = 0 minutes. Guggulsterone impairs thrombus 
formation (n=4-8; P<0.02 versus vehicle). 
 
Figure 6: Guggulsterone inhibits vascular smooth muscle cell activation 
A. Guggulsterone inhibits vascular smooth muscle (VSMC) proliferation (n=11; 
P<0.05 versus control). B. Guggulsterone inhibits vascular smooth muscle (VSMC) 
migration (n=5; P<0.05 versus control). 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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